Clinical Data and Spacelabs Healthcare Enter Partnership to Promote Clinical Data's Drug-Induced Long QT Pharmacogenomics Services.

NEWTON, Mass. -- Clinical Data, Inc. (NASDAQ: CLDA) and Spacelabs Healthcare Clinical Trial Services today announced a partnership to offer Clinical Data's proprietary services related to the testing of drug-induced QT prolongation to Spacelabs' customers through Clinical Data's service division, Cogenics[TM]. This agreement will assist drug development researchers and governmental regulatory agencies in improving the utility of the trials in detecting or ruling out meaningful QT prolonging effects by controlling for genetic variables. The pharmacogenomics analyses will be performed at the New Haven, Conn. laboratories of Clinical Data.

Robert Bondaryk, Senior Vice President and General Manager of Cogenics, commented, "More than 50 medications, many of them common, can prolong the QT interval in otherwise healthy people and cause a form of acquired long QT syndrome known as drug-induced long QT syndrome. We are very pleased to enter into this collaboration with Spacelabs, who has the ability to provide these services globally.

Jim Roop, President, Clinical Trial Services, stated, "We are excited to partner with Cogenics and offer our customer base additional options for meeting the regulatory requirements in their drug development programs. There is much concern in the industry about the problem of Long QT Syndrome. This partnership will allow Spacelabs to incorporate genetic testing for drug-induced QT prolongation into all stages of clinical trials, offering our clients the highest level of cardiac safety services."

About Long QT Testing Services

Drug-induced QT (DI-LQT) prolongation is a leading cause of delays in drug development and drug withdrawals from the market. Over the past few years, several drugs have been pulled from the market as a result of adverse effects related to cardiac safety. In response, regulatory agencies are requesting a definitive or Thorough QT (TQT) study prior to marketing approval. These studies are meant to prevent development expense by either confirming a drug's negligible effect on QT or identifying drugs that seriously impact QT at an early stage. In the event of a positive TQT, ICH E14 recommends that outliers be evaluated for risk factors including genotyping for LQTS to identify mutations in people with inherited cardiac channelopathies such as Long QT Syndrome (LQTS) and Brugada Syndrome.

Clinical Data's Long QT Testing Services utilize intellectual property from CLDA's proprietary FAMILION([R]) test. The test is performed on blood and identifies mutations in people with inherited cardiac channelopathies by examining the sequences of five cardiac ion channel genes that have been shown to cause disorders.

About Clinical Data, Inc.

Clinical Data, Inc. is a global biotechnology company unlocking the potential of molecular discovery, from targeted science to better healthcare. Its PGxHealth division focuses on genetic test and biomarker development to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics division provides molecular and pharmacogenomics services to both research and regulated environments. Its Vital Diagnostics division offers in vitro diagnostics solutions for the clinical laboratory. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists, and health plans worldwide.

About Spacelabs Healthcare, Inc.

Spacelabs Healthcare, Inc. (www.spacelabshealthcare.com) is an international developer, manufacturer and distributor of medical equipment and services including solutions for patient monitoring and connectivity, anesthesia delivery and ventilation, diagnostic cardiology and supplies and accessories selling to hospitals, clinics and physician offices. Additionally, the company provides centralized cardiac safety and diagnostic services (ECG, Holter, ABP, and Event Monitoring) to biopharmaceutical companies undertaking clinical trials.

The company has established brand names in both medical devices and medical services such as "Spacelabs," "Blease" and "Del Mar Reynolds." It employs approximately 1,100 personnel in its offices located in the United States, UK, Canada, France, Germany, Finland, India and Singapore.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to statements regarding: our ability to successfully integrate the operations, business, technology and intellectual property obtained in our acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: whether our PGxPredict tests will gain wide acceptance in the market; the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety; our ability to achieve the expected synergies and operating efficiencies from all of our acquisitions; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; the development of and our ability to take advantage of the market for pharmacogenetic and biomarker products and services; general economic downturns; and other risks contained in our various SEC reports and filings, including but not limited to our Quarterly Report on Form 10-Q for the quarter ended December 31, 2006, and our subsequent Current Reports on Form 8-K filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Internet Website: www.clda.com